Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases.

Abstract

PURPOSE:

This study was done to evaluate the effectiveness of radioembolisation of liver metastases with yttrium 90 (Y-90) in patients with no response to chemotherapy.

MATERIALS AND METHODS:

From February 2005 to January 2008, we treated 110 patients affected by liver metastatic disease from colorectal, breast, gastric, pancreatic, pulmonary, oesophageal and pharyngeal cancers and from cholangiocarcinoma and melanoma. We excluded patients with bilirubin level >1.8 mg/dl and pulmonary shunt >20% but not patients with minor extrahepatic metastases.

RESULTS:

We obtained a complete /partial response in 45 patients, stable disease in 42 patients and progressive disease in 23 patients. In 90 cases, we obtained a decrease in specific tumour marker level. The technical success rate was 96%, and technical effectiveness estimated at 3 months after treatment was 83.6%. Side effects were grade 4 hepatic failure in one case, grade 2 gastritis in six cases and grade 2 cholecystitis in two cases. The median survival and progression-free survival calculated by Kaplan-Meier analysis were 323 days and 245 days, respectively.

CONCLUSIONS:

According to our 3-year experience, Y-90 radioembolisation (SIR-spheres) is a feasible and safe method to treat liver metastases with an acceptable level of complications and a good response rate.

• Authors: R Cianni, C Urigo, E Notarianni, A Saltarelli, A D'Agostini, M Iozzino, T Dornbusch, E Cortesi
• Journal: La Radiologia medica (Radiol Med) Vol. 115 Issue 4 Pg. 619-33 (Jun 2010) ISSN: 1826-6983 [Electronic] Italy
• PMID: 20091135 (Publication Type: Journal Article)

Chemical References

• Yttrium Radioisotopes

Topics

• Dose-Response Relationship, Radiation
• Embolization, Therapeutic (methods)
• Humans
• Liver Neoplasms (diagnosis, radiotherapy, secondary)
• Male
• Middle Aged
• Treatment Outcome
• Yttrium Radioisotopes (administration & dosage, therapeutic use)